Preclinical evaluation of Vaxfectin<sup>®</sup>-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines

Smith, Larry; Wodal, Walter; Crowe, Brian A.; Kerschbaum, Astrid; Bruehl, Peter; Schwendinger, Michael G.; Savidis-Dacho, Helga; Sullivan, Sean; Shlapobersky, Mark; Hartikka, Jukka; Rolland, Alain; Barrett, Perry; Kistner, Otfried

doi:10.4161/hv.24209

Cited by 9 publications

(7 citation statements)

References 55 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If therer is a influenza pandemic in somewhere, the Pharmaceutical Factory cannot prepare enough vaccines, because of the insufficient supply of embryo eggs, in a short period of time. The use of Vero cells lines for vaccine virus growth could largely overcome these problems, provided that the yields were satisfactory and safety issues could be addressed [Smith et al, ; van der Velden et al, ].…”

Section: Discussionmentioning

confidence: 99%

Construction high-yield candidate influenza vaccine viruses in Vero cells by reassortment

Yang

et al. 2016

J. Med. Virol.

View full text Add to dashboard Cite

Usage of influenza vaccine is the best choice measure for preventing and conclusion of influenza virus infection. Although it has been used of chicken embryo to produce influenza vaccine, following with WHO recommended vaccine strain, there were uncontrollable factors and its deficiencies, specially, during an influenza pandemic in the world. The Vero cells are used for vaccine production of a few strains including influenza virus, because of its homology with human, recommended by WHO. However, as known most of the influenza viruses strains could not culture by Vero cells. It was used two high-yield influenza viruses adapted in Vero cells as donor viruses, such as A/Yunnan/1/2005Va (H3N2) and B/Yunnan/2/2005Va (B), to construct high-yield wild influenza virus in Vero cells under antibody selection pressure. After reassortment and passages, it obtained the new Vaccine strains with A/Tianjin/15/2009Va (H1N1), A/Fujian/196/2009Va (H3N2) and B/Chongqing/1384/2010Va (B), which was not only completely keeping their original antigenic (HA and NA), but also grown well in Vero cells with high-yield. All results of gene analysis and HA, HI shown that this reassortment method could be used to find new direction to product the influenza vaccine. J. Med. Virol. 88:1914-1921, 2016. © 2016 Wiley Periodicals, Inc.

show abstract

Section: Discussionmentioning

confidence: 99%

Construction high-yield candidate influenza vaccine viruses in Vero cells by reassortment

Yang

et al. 2016

J. Med. Virol.

View full text Add to dashboard Cite

show abstract

“…In contrast, a direct modulation of immune pathways by the compound seems to be more crucial for the increase in immunogenicity [ 61 ]. The adjuvant is also being tested with other vaccine techniques, such as inactivated pathogens [ 14 , 15 , 16 , 17 , 18 , 62 ]. Vaxfectin has been successfully used together with a variety of DNA vaccines in small animal models [ 63 , 64 , 65 ].…”

Section: Chemical Adjuvantsmentioning

confidence: 99%

Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases

Grünwald

Ulbert

2015

Clin Exp Vaccine Res

View full text Add to dashboard Cite

Advantages of DNA vaccination against infectious diseases over more classical immunization methods include the possibilities for rapid manufacture, fast adaptation to newly emerging pathogens and high stability at ambient temperatures. In addition, upon DNA immunization the antigen is produced by the cells of the vaccinated individual, which leads to activation of both cellular and humoral immune responses due to antigen presentation via MHC I and MHC II molecules. However, so far DNA vaccines have shown most efficient immunogenicity mainly in small rodent models, whereas in larger animals including humans there is still the need to improve effectiveness. This is mostly due to inefficient delivery of the DNA plasmid into cells and nuclei. Here, we discuss technologies used to overcome this problem, including physical means such as in vivo electroporation and co-administration of adjuvants. Several of these methods have already entered clinical testing in humans.

show abstract

“…For examples, addition of the MF-59 to subunit influenza vaccine leads to higher HI and neutralizing antibody titers. 25 However, Vaxfectin, a cationic lipid-based adjuvant, combined with seasonal influenza vaccine can significantly increase both specific antibody and T cell responses. The potential role of APG-induced T cell responses in the efficacy of influenza vaccine will be investigated further.…”

Section: Discussionmentioning

confidence: 99%

Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines

Bao

Wang

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Influenza viral infections are significant global public health concerns due to the morbidity and mortality associated with acute respiratory disease, secondary complications, and pandemic threats; thus, continuous efforts have been made to develop potent influenza vaccines. In this study, 3 different mucosal adjuvants-alkyl polyglycoside (APG), gellan gum, and chitosan (CS)-were evaluated for their efficacy in intranasal A/H1N1 or B split influenza vaccines administered to BALB/c mice. Protective immunity was monitored by serum analysis for IgG, hemagglutination inhibition (HI), and neutralizing antibody levels, as well as mucosal IgA levels in nasal and pulmonary lavage fluids. Survival, body weight, lung viral titer, and pulmonary immunopathology were also examined following lethal influenza challenge. Notably, all adjuvants amplified the IgG and IgA immune responses (not detected in immunization of influenza B) and increased survival rate compared with controls administered adjuvantfree intranasal vaccines. Alternatively, intramuscular immunization stimulated IgG production, but had no effect on IgA levels. Our collective analysis identified that APG was the most effective intranasal adjuvant, as all mice survived influenza challenge with limited body weight loss, viral titer, and pulmonary pathology, similar to those observed with intramuscular vaccination. This evidence supports that APG can elicit both systemic and mucosal immunity, and may be an effective adjuvant in intranasal split influenza A/H1N1 and B vaccines.

show abstract

Preclinical evaluation of Vaxfectin^®-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines

Cited by 9 publications

References 55 publications

Construction high-yield candidate influenza vaccine viruses in Vero cells by reassortment

Construction high-yield candidate influenza vaccine viruses in Vero cells by reassortment

Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases

Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines

Contact Info

Product

Resources

About

Preclinical evaluation of Vaxfectin®-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines

Cited by 9 publications

References 55 publications

Construction high-yield candidate influenza vaccine viruses in Vero cells by reassortment

Construction high-yield candidate influenza vaccine viruses in Vero cells by reassortment

Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases

Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines

Contact Info

Product

Resources

About

Preclinical evaluation of Vaxfectin^®-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines